The pandemic of COVID-19 has posed an unprecedented threat to global public health. However, the interplay between the viral pathogen of COVID-19, SARS-CoV-2, and host innate immunity is poorly understood. Here we show that SARS-CoV-2 induces overt but delayed type-I interferon (IFN) responses. By screening 23 viral proteins, we find that SARS-CoV-2 NSP1, NSP3, NSP12, NSP13, NSP14, ORF3, ORF6 and M protein inhibit Sendai virus-induced IFN-β promoter activation, whereas NSP2 and S protein exert opposite effects. Further analyses suggest that ORF6 inhibits both type I IFN production and downstream signaling, and that the C-terminus region of ORF6 is critical for its antagonistic effect. Finally, we find that IFN-β treatment effectively blocks SARS-CoV-2 replication. In summary, our study shows that SARS-CoV-2 perturbs host innate immune response via both its structural and nonstructural proteins, and thus provides insights into the pathogenesis of SARS-CoV-2.
A novel human coronavirus (SARS-CoV-2) emerged in December 2019 and caused 6,931,000 cases, including 400,857 deaths involved 185 countries, areas, or territories as of June 8, 2020 (https://covid19.who.int/), posing a huge threat to global public health. The World Health Organization (WHO) has announced COVID-19 as a pandemic on 11 March 2020 (www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen). SARS-CoV-2 belongs to the Coronaviridae family, Orthocoronavirinae subfamily, Betacoronaviruses genus, Sarbecovirus subgenus1. After SARS-CoV, SARS-CoV-2 is the second virus that originated from bats and could infect human beings of Sarbecovirus1,2,3. The pathogenesis of SARS-CoV-2 remains largely unknown.
Similar to other viruses in Sarbecovirus, the genome of SARS-CoV-2 is approximately 29.7 kb long with a short untranslated region (UTR) in 5′ and 3′ terminus1,3. The SARS-CoV-2 genome encodes spike (S), envelope (E), membrane (M), nucleocapsid (N) proteins, accessory proteins 3, 6, 7a, 7b, 8, and 9b, and comprises a large open reading frame (ORF) encoding 1ab1, which is further cleaved into 15 nonstructural proteins (NSP1–10, 12–16) by its papain-like proteinase (NSP3) and 3C-like proteinase (NSP5)4. Different from SARS-CoV, the SARS-CoV-2 genome encodes complete ORF8 but no 8b. The genome of SARS-CoV-2 has 79% nucleotide identity with that of SARS-CoV1.
Innate immunity is the first line of host defense against virus infections and is initiated by recognition of pathogen-associated molecular patterns (PAMPs) via host pattern recognition receptors (PRRs)5,6,7,8. The type-I interferon system is a vital part of the innate immune response. The double-strand RNA (dsRNA), which is generated during coronavirus genome replication and transcription9,10, could be recognized by the RIG-I-like receptors (RLRs), including the retinoic acid-inducible gene I (RIG-I) and/or melanoma differentiation gene 5 (MDA5) in the cytoplasm11,12, or by toll-like receptors (TLRs) in the endosome13,14. The two caspase activation recruitment domains (CARD) of RIG-I and MDA5 could interact with the adapter mitochondrial antiviral signaling protein (MAVS, also termed as IPS-1, VISA, and Cardif)15,16,17,18, which subsequently recruits the two IKK-related kinases, TANK-binding kinase 1 (TBK1) and inducible IκB kinase (IKKi), both of which phosphorylate interferon regulatory factor 3/7 (IRF3/7)19. After phosphorylation and dimerization, IRF3/7 translocates to the nucleus to activate the expression of IFN-α/β20,21. Concomitantly, MAVS recruits TANK1 by TRAF6 and activates the NF-κB signaling pathway, which could promote the cytokines production15. Alternatively, PAMPs could be recognized by Toll-like receptors (TLRs), and the downstream adapter proteins TRIF or MyD88 could signal to induce cytokines and chemokines production13,22,23.
Once secreted, IFN-α/β function as autocrine and paracrine factors to induce the expression of IFN-stimulated genes (ISGs) via the Janus activated kinase (Jak)-signal transducers and activators of transcription (STAT1) signaling pathways. ISGs are the main effectors of IFN-mediated antiviral responses24. Accordingly, viruses have developed diverse strategies to counteract interferon responses. Coronavirus such as SARS-CoV could inhibit interferon production by (1) avoiding being recognized by PRRs25,26, (2) compromising RIG-I or TLRs signaling27, and (3) impeding IRF3 activation28. Moreover, SARS-CoV could antagonize the signaling pathway downstream of IFN production by blocking the nuclear translocation of STAT129. However, whether and how SARS-CoV-2 antagonizes IFN production and signaling is not clear.
Several SARS-CoV proteins have been identified as IFN antagonists. The accessory open reading frames 6 (ORF6) play a critical role in counteracting host antiviral response and viral replication30. ORF6 suppresses the Sendai virus (SeV)-mediated IFN induction by inhibiting the phosphorylation and nuclear translocation of IRF331. ORF6 also inhibits the STAT1 nuclear translocation without affecting its phosphorylation31, possibly by interacting with KPNA2, which mediates the KPNAB binding to ORF6-KPNA2 complex29.
Here, we investigate the interaction between SARS-CoV-2 and host antiviral responses. We demonstrate that host innate immune response is targeted by multiple viral proteins, among which ORF6 potently perturbs signaling pathways both upstream and downstream of IFN production. Moreover, we show that SARS-CoV-2 is susceptible to IFN treatment. Our results provide mechanistic insights into interactions between SARS-CoV-2 and the host.
SARS-CoV-2 induces substantial but delayed IFN-β production
To understand the interaction between SARS-CoV-2 and the host antiviral response, we firstly examined whether SARS-CoV-2 infection induces the expression of IFN-β and IFN-inducible genes 56 (ISG56). Calu-3, an airway epithelial cell line, were mock-infected or infected with SARS-CoV-2. In parallel, cells were infected or transfected with SeV and poly (I:C), respectively, both of which are often used to stimulate antiviral signaling pathways. At different time points postinfection (hpi), cells were harvested for determining host and viral RNA levels by quantitative PCR analysis, and the supernatants were collected and subjected to TCID50 assays for measuring viral titers. SARS-CoV-2 replicated well in the Calu-3 cells, as seen from the increased number of viral transcripts and replicative viruses with prolonged infection time (Fig. 1a, b). Upon SARS-CoV-2 infection, the expressions of IFN-β and ISG56 are only marginally elevated until 12 hpi but are dramatically induced at 24 hpi (Fig. 1c, d). In contrast, SeV infection stimulates the expression of IFN-β and ISG56 as early as 4 hpi and peaked at 8 hpi, even though SeV RNA is much less produced compare to SARS-CoV-2 (Fig. 1e–g). Moreover, poly (I:C) induced IFN-β and ISG56 expression in a similar kinetic pattern to that detected in SeV infection (Fig. 1h, i). These observations show that SARS-CoV-2 infection stimulates substantial but delayed IFN production, suggesting that SARS-CoV-2 infection attenuated host antiviral response.
SARS-CoV-2 proteins interfere with IFN-β activation
To explore which proteins of SARS-CoV-2 could regulate the innate immune responses, we cloned SARS-CoV-2 genes after codon optimization, including nonstructural genes NSP1-10, NSP12–16, structural genes S, E, M, and N, and accessory protein genes ORF3, ORF6, ORF7a, and ORF8 (Fig. 2a). ORF7b was not included due to the small size of 43 amino acids (a.a.). An NSP3 fragment (nucleotide sequence 2250–3183), which encode the papain-like protease 2 domain, was cloned due to the difficulties in synthesizing the full-length NSP3 of 5835 bp. Western blot showed that all genes could be expressed, albeit at different levels (Fig. 2b). Next, we evaluated the effect of individual SARS-CoV-2 proteins on IFN-β promoter activation. 293T cells were transiently transfected with the vector plasmid or with plasmids expressing SARS-CoV-2 proteins, along with an IFN-β promoter-driven luciferase reporter plasmid (pIFN-β-Luc) and a control pRL-TK plasmid. After 24 h, cells were stimulated with SeV for 12 h, and the luciferase activity was determined. We found that SARS-CoV-2 proteins exerted divergent effects on SeV-induced IFN-β promoter activation. The expressions of NSP1, NSP3, NSP12, NSP13, NSP14, ORF3, ORF6, and M significantly inhibited SeV-mediated IFN-β activation, whereas NSP2 and S protein exhibited the opposite effects (Fig. 2c). Moreover, NSP1, NSP3, NSP12, NSP13, NSP14, ORF3, ORF6, E, and M were able to recapitulate their inhibitory activity when IFN-β promoter activity was stimulated upon the overexpression of RIG-IN (the constitutively active N-terminal domains of RIG-I) or MDA5 (Fig. 2d, e). The expression levels of SeV protein, RIG-IN, and MDA5 were shown in Fig. 2f–h. These results suggest that the SARS-CoV-2 proteins may play pleiotropic roles in regulating host innate immune response.
SARS-CoV-2 ORF6 inhibits IFN-β activation
Considering that SARS-CoV-2 ORF6 shares the least sequence similarity with SARS-CoV ORF6 (Supplementary Fig. 1a, b)1, which was shown to counteract host antiviral response at multiple steps29,31, we focused on the function of SARS-CoV-2 ORF6. Immunofluorescence experiments showed that ORF6 was predominantly localized in the cytoplasm and partially colocalized with the Golgi apparatus and endoplasmic reticulum markers (Supplementary Fig. 1c). In a dose-dependent manner, ORF6 inhibited IFN-β promoter activation induced by both SeV and the high molecular weight poly(I:C), which are thought to stimulate RIG-I and MDA5 signaling pathway, respectively (Fig. 3a, b). Further, we examined at which step of the signaling cascade the ORF6 blocks the antiviral innate immune response. We cotransfected increasing amounts of ORF6 expression plasmids with plasmids encoding key signaling proteins involved in innate antiviral response and determined the activation of the IFN-β promoter. As shown in Fig. 3c–f, overexpression of ORF6 inhibited RIG-IN, MDA5, MAVS, and IRF3-5D (a constitutively active IRF3 mutant)-triggered IFN promoter activation in a dose-dependent manner. These results demonstrated that ORF6 inhibited IFN-β production at the level of or downstream of IRF3 activation. Moreover, SARS-CoV-2 ORF6 and SARS-CoV ORF6 showed comparable inhibitory effects on MAVS and IRF3-induced IFN-β promoter activation (Fig. 3g, h). Finally, immunofluorescence analyses showed that SeV-induced IRF3 nuclear translocation was prevented in cells overexpressing ORF6 (Fig. 3i), corroborating that ORF6 blocks IRF3 activation.
ORF6 suppresses IRF3 activation via its C-terminus
Because the C-terminus of SARS-CoV ORF6 is critical for its antagonistic activity29, we then examined the role of the C-terminus of SARS-CoV-2 in IFN inhibition. Three ORF6 variants harboring C terminal mutations, including ORF6-M1 (a.a. 49–52 substituted with alanines), ORF6-M2 (a.a.53–55 substituted with alanines), and ORF6-M3 (a.a. 56–61 substituted with alanines), were generated (Fig. 4a). Then, the effect of wildtype and ORF6 mutants on the IFN promoter activation was assayed. We found that overexpression of ORF6-M1 inhibited IFN-β promoter activation triggered by RIG-IN, MDA5, MAVS, and IRF3-5D to a comparable or lower level to that observed in the overexpression of wildtype ORF6 (Fig. 4b–e). In contrast, ORF6-M2 and ORF6-M3 exhibited severely impaired inhibitory activity. Moreover, SeV-induced IRF3 nuclear translocation was impeded by the overexpression of wildtype and the M1 form of ORF6, while ORF6-M2 and ORF6-M3 had no effects (Supplementary Fig. 2). Therefore, we conclude that the C-terminal tail of SARS-CoV-2 ORF6 from a.a. 53 to 61 are essential for its antagonistic activity, whereas a.a. 49 to 52 are dispensable.
ORF6 inhibits the ISRE and ISG56 promoter’s activation
We further examined whether SARS-CoV-2 proteins affect downstream signaling of type I IFN. To do this, cells were cotransfected with the vector plasmid or with plasmids expressing SARS-CoV-2 proteins, along with an interferon-stimulated response element (ISRE) reporter plasmid. After 24 h, cells were treated with 800 U/ml IFN-β for 12 h and then subjected to dual luciferase assay. This assay revealed that NSP1, NSP3, NSP13, NSP14, ORF6, ORF8, N, and S proteins inhibited IFN-β-induced ISRE promoter activity, while NSP6, NSP9, NSP12, and E proteins showed stimulatory effects (Fig. 5a). We next focus on ORF6. Overexpression of ORF6 inhibited luciferase expression from both ISRE and ISG56 promoter in a dose-dependent manner (Fig. 5b, c). Because expression from ISRE or ISG56 promoter after IFN-β treatment depends on IFN receptor signaling, these data demonstrated that ORF6 antagonizes signaling downstream of IFN. Further, SARS-CoV ORF6 and SARS-CoV-2 ORF6 showed a comparable inhibitory effect on the IFN-β-induced ISRE or ISG56 promoter activation (Fig. 5d, e).
ORF6 inhibits STAT1 nuclear translocation via its C-terminus
We then investigated the mechanism by which ORF6 inhibits IFN signaling. After binding to its receptor, IFN-β activates the Jak-STAT pathway, in which the Jak1 and Tyk2 kinases phosphorylate STAT1 and STAT2, triggering their dimerization and nuclear translocation24. In 293T cells, IFN-induced STAT1 phosphorylation remains intact in the presence of SARS-CoV and SARS-CoV-2 ORF6 (Fig. 6a). In contrast, expression of SOCS1, a well-established inhibitor of Jak kinases, substantially inhibited STAT1 phosphorylation (Fig. 6a). These data suggested that ORF6 does not interfere with signaling cascade upstream of STAT1 phosphorylation. Similar results were observed in Vero cells, which are deficient in type I IFN genes but retain the IFN receptor (Supplementary Fig. 3).
Having observed that ORF6 inhibited ISRE/ISG56 promoter activation while not affecting STAT1 phosphorylation, we then asked whether ORF6 overexpression regulates the translocation of STAT1 from the cytoplasm to the nucleus. Cells were transfected with plasmids expressing SARS-CoV or SARS-CoV-2 ORF6. After 24 h, cells were treated with IFN-β for 30 min, and the localization of STAT1 was analyzed. Immunofluorescence analyses showed that cells expressing either SARS-CoV ORF6 or SARS-CoV-2 ORF6 displayed rare STAT1 nuclear localization, whereas ORF6-null cells showed substantial STAT1 nuclear distribution (Fig. 6b, c), indicating that SARS-CoV and SARS-CoV-2 ORF6 inhibited IFN-β-triggered STAT1 nuclear translocation. Finally, we detected the effect of SARS-CoV-2 ORF6 C-terminal variants on STAT1 activation. We found that, to a comparable extent, both ORF6-M1 and wildtype ORF6 inhibited IFN-induced ISRE/ISG56 promoter activation and translocation (Fig. 7a–c), whereas failed to affect IFN-stimulated STAT1 phosphorylation (Supplementary Fig. 4). ORF6-M2 and ORF6-M3 exerted no effects in those assays. Moreover, immunofluorescence analyses with an antibody specific to phospho-STAT1 showed similar results that were observed in Fig. 7c (Supplementary Fig. 4b). Together, these data suggested that the C-terminal tail a.a. 53–61 are essential for ORF6′s activity in antagonizing STAT1 nuclear translocation but not phosphorylation.
SARS-CoV-2 is sensitive to IFN-β treatment
Finally, we examined the effect of IFN-β treatment on SARS-CoV-2 infection. Calu-3 cells were pretreated with 100 or 500 U/ml of recombinant human IFN-β for 18 h to trigger IFN response, whose activation was then verified by the upregulated expression of ISG genes ISG54 and ISG56 (Fig. 8a, b). Then, cells were infected with SARS-CoV-2 at an MOI of 0.5 for 24 h. We found that IFN-β treatment decreased the amount of viral transcripts and the production of replicative viruses in a dose-dependent manner (Fig. 8c, d). Collectively, the results suggest that SARS-CoV-2 is sensitive to IFN-β treatment.
The viral antagonism of host innate immune response is critical for virus replication and often determines the outcomes of the infection. The evasion of host immune surveillance will give rise to the uncurbed viral replication, which could cause hyperactive host proinflammatory response, termed as hypercytokinemia or cytokine storm, and eventually lead to detrimental outcomes32. In the severe cases of COVID-19, hypercytokinemia and acute respiratory distress syndrome (ARDS) were observed33,34,35, while the underlying mechanism remains unclear. In the current study, we revealed that SARS-CoV-2 induced an aberrant type-I IFN response in cultured cells, as the expressions of IFN-β and ISG56 were barely induced early during viral infection, while surged at late time points. This delayed antiviral response may provide a window for virus replication. Indeed, large amounts of viral transcripts were observed before the IFN induction in SARS-CoV-2-infected cells. Consonant with this, high viral loads were detected in COVID-19 cases soon after symptom onset36. Thus, we postulate that the lack of timely and adequate antiviral response may be central to the COVID-19 pathogenesis.
It is known that SARS-CoV has developed multiple strategies to antagonize the host antiviral response37. Among those, ORF6 was thought to play a critical role as this protein limits both IFN production and downstream signaling29,31. Of note, ORF6 of SARS-CoV-2 shares the least sequence similarity with that of SARS-CoV (~66%), and the disparity is mainly observed in the C-terminal sequence. Moreover, SARS-CoV-2 has a two amino acid truncation in its ORF6 terminus tail as compared to SARS-CoV. Considering that the C-terminus tail of SARS-CoV ORF6 is required for its antagonistic activity29, we inferred ORF6 maintains equivalent function in SARS-CoV-2. In the current study, we revealed that ORF6 of SARS-CoV-2 and SARS-CoV exhibited similar cellular distribution and comparable ability in inhibiting IRF3 activation and STAT1 nuclear translocation. Thus, although genetically changed, SARS-CoV-2 ORF6 retained its full ability in antagonizing host innate immune response, suggesting that this antagonistic function is evolutionarily important. Of note, the last several amino acids of the ORF6 C-terminus tail, DEEPMELDYP in SARS-CoV29, and DEEQPMEID in SARS-CoV-2, are indispensable for ORF6′s function in blocking IRF3 and STAT1 activation. Therefore, we hypothesized that these amino acids, which are enriched with negatively charged residues, may provide an interface that mediates ORF6′s interaction with host proteins, and thus exert its antagonistic activity. This sequence could be a therapeutic target candidate because a small blocking peptide against this motif could potentially mitigate SARS-CoV-2′s virulence. Recently, in an effort to map SARS-CoV-2-human protein–protein interaction (PPIs), Gordon et al. identified that ORF6 interacts with NUP98 and RAE1, which form a nuclear pore complex38. It is possible that ORF6 blocks IRF3 and STAT1 nuclear translocation by interacting with these nuclear pore proteins. This hypothesis awaits further investigations.
Other than ORF6, several SARS-CoV proteins, including NSP1, ORF3b, M, N, and others, may act as IFN antagonists37. Here, we found that NSP1 and M of SARS-CoV-2 also inhibited SeV-induced IFN production. Moreover, this inhibition effect was observed when overexpressing NSP12 and NSP13, which are enzymes responsible for genomic replication of coronaviruses39. Of note, in the PPI study38, NSP13 was identified to interact with TBK1 and its adapter TBKBP1. Because TBK1 plays essential roles in innate antiviral response, we speculate that NSP13 could mitigate IFN production inhibiting TBK1 activity. Intriguingly, NSP2 and S of SARS-CoV-2 showed a significant stimulatory effect on the IFN induction. This unexpected observation confounded the overall effect of the SARS-CoV proteins on the innate antiviral immune response. Recent studies suggested that SARS-CoV-2 could induce expression of multiple ISGs35,40, which is barely detected in SARS-CoV infection41; we speculate that the immuno-stimulatory effects of SARS-CoV-2 proteins may contribute to this induction.
In agreement with recent findings42,43, we found that SARS-CoV-2 is sensitive to IFN pretreatment, suggesting that IFN therapy could be an option for COVID-19 treatment. It is of interest to identify ISGs that directly and specifically inhibit SARS-CoV-2 infection and replication. Overall, our study characterized the interplay between SARS-CoV-2 and host innate immunity, and provided mechanistic insight in the immune evasion of SARS-CoV-2 mediated by viral proteins. These findings could advance our understandings of the pathogenesis of SARS-CoV-2.
Cell lines and viruses
Human 293T (ATCC, #CCL-11268;) cells, 293 (ATCC, #CRL-1573), Calu-3 (ATCC, #HTB-55;), HeLa (ATCC, #CCL-2;), and Vero (ATCC, #CCL-81,) cells was cultured in Dulbecco’s modified Eagle’s medium (Invitrogen, Carlsbad, CA) supplemented with 10% heat-inactivated fetal bovine serum (FBS) (HyClone, Logan, UT), 100 U/ml penicillin, and 100 U/ml streptomycin at 37 °C in a 5% CO2 humidified atmosphere. Low passage HeLa and Vero cells after directly purchasing from ATCC were used, and all cells were tested for mycoplasma-free. The SARS-CoV-2 virus was isolated from respiratory samples of confirmed COVID-19 patients by inoculating onto Vero cells1 and was propagated in Vero cells and used in this study. Cells were infected with SARS-CoV-2 at a multiplicity of infection (MOI) of 0.5. Unbound virus was washed away after 1 h, and cells were then cultured with fresh medium supplemented with 2% FBS. All experiments with the SARS-CoV-2 virus were conducted in the BSL-3 laboratory.
Plasmids and antibodies
The 23 genes of SARS-CoV-2 (IPBCAMS-WH-01/2019 strain, no. EPI_ISL_402123) were optimized by Gene Designer 1.0 and cloned to vector pCMV6-entry expression vector with the FLAG-tag or HA-tag at C-terminus. Plasmids Flag-RIG-I, Flag-RIG-IN, Flag-MDA5, HA-MAVS, pGL3-IFN-β–Luc, IRF3-5D-Flag, and pRL-TK have been described elsewhere42. The mutated variants of the SARS-CoV-2 ORF6-tagged Flag were constructed by using a Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA). All variants were confirmed by subsequent sequencing.
The antibodies used in this research were: Flag antibody from Sigma-Aldrich (1:4000, Cat# F3165); β-actin antibody from Sigma–Aldrich (1:4000, Cat# A5441); HA antibody from Sigma–Aldrich (1:10,000, Cat# H9658); STAT1 antibody from Cell Signaling technology (1:1000, Cat# 9172); P-STAT1 antibody from Thermo Fisher (1:1000, Cat# 700349); Sev antibody from MBL (1:2000, PD029C1). Dual-Luciferase® Reporter Assay System was purchased from Progema (Madison, WI). IRDye 800-labeled IgG and IRDye 680-labeled IgG secondary antibodies were purchased from Li-Cor Biosciences (Lincoln, NE).
Fifty percent tissue culture infectious dose (TCID50) assays
Samples were stored at −80 °C and repeatedly freeze-thaw three times before being processed for determination. Vero cells in 96-well plates were cultured overnight with 80% confluency. Using dilution blocks, samples were serially diluted 10-fold from 10−1 to 10−8 in opti-MEM. 100 μl/well of each dilution were placed onto the Vero cells in octuplicate and incubated at 37 °C with 5% CO2 for 1 h. Then the culture supernate was replaced with 1% BSA of opti-MEM and incubated for 4 days. Then the cytopathic effect (CPE) was evaluated under a microscope and recorded.
293T cells cultured in 24-well plates were transfected with a control plasmid or plasmids expressing of RIG-IN, MDA5, MAVS, or IRF3-5D, along with luciferase reporter plasmids or plasmids expressing viral proteins. Cells were harvested, and cell lysates were used to determine luciferase using a Dual Luciferase Reporter Assay System (Promega). The firefly luciferase activities were normalized to Renilla luciferase activities44.
Cells were washed with PBS buffer and fixed with 4% formalin. Then cells were permeabilized with 0.5% Triton X-100. After cells were washed with PBS, they were blocked and stained with primary antibodies, followed by staining with an Alexa Fluor 488 secondary antibody45. Nuclei were stained with DAPI (Sigma). The antibodies used in this research were: IRF3 antibody from Cell Signaling technology (1:200, Cat# 11904); STAT1 antibody from Cell Signaling technology (1:400, Cat# 14994); P-STAT1 antibody from Cell Signaling technology (1:400, Cat# 9167); Calnexin antibody from Cell Signaling technology (1:50, Cat# 2679); GolgiB1 antibody from Sigma-Aldrich (1:500, Cat# HPA011008). Fluorescence images were obtained and analyzed using a laser scanning confocal microscope (Leica TCS SP5).
Quantitative real-time PCR analysis
Total RNA was extracted by using TRIzol reagent (Invitrogen, Carlsbad, CA) and reverse transcript to cDNA by M-MLV Reverse Transcriptase (Promega, Madison, WI). cDNAs were prepared for the real-time PCR by using TB Green Premix Ex (Takara, Kusatsu, Shiga). The Primer sequences of IFNB, ISG56, ISG54, P gene of SeV were provided in Supplementary Table 1. The Primer sequence specific for the SARS-CoV-2 was available from J.W. upon request.
The two-tailed Student’s t-test was used for two-group comparisons. The values *P < 0.05, **P < 0.01, and ***P < 0.001 were considered significant. ns stands for not significant.
Further information on research design is available in the Nature Research Reporting Summary linked to this article.
All other data are included in the Supplemental Information or available from the authors upon reasonable requests. Source data are provided with this paper.
Ren, L. L. et al. Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study. Chin. Med. J. 133, 1015–1024 (2020).
Gorbalenya, A. E. et al. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat. Microbiol. 5, 536–544 (2020).
Lu, R. et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 395, 565–574 (2020).
Marra, M. A. et al. The Genome sequence of the SARS-associated coronavirus. Science 300, 1399–1404 (2003).
Akira, S., Uematsu, S. & Takeuchi, O. Pathogen recognition and innate immunity. Cell 124, 783–801 (2006).
Alexopoulou, L., Holt, A. C., Medzhitov, R. & Flavell, R. A. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 413, 732–738 (2001).
Medzhitov, R., Preston-Hurlburt, P. & Janeway, C. A. Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388, 394–397 (1997).
Pichlmair, A. et al. RIG-I-mediated antiviral responses to single-stranded RNA bearing 5′-phosphates. Science 314, 997–1001 (2006).
Kindler, E., Thiel, V. & Weber, F. Interaction of SARS and MERS coronaviruses with the antiviral interferon response. Adv. Virus Res. 96, 219–243 (2016).
Zielecki, F. et al. Human cell tropism and innate immune system interactions of human respiratory coronavirus EMC compared to those of severe acute respiratory syndrome coronavirus. J. Virol. 87, 5300–5304 (2013).
Li, J., Liu, Y. & Zhang, X. Murine coronavirus induces type I interferon in oligodendrocytes through recognition by RIG-I and MDA5. J. Virol. 84, 6472–6482 (2010).
Roth-Cross, J. K., Bender, S. J. & Weiss, S. R. Murine coronavirus mouse hepatitis virus is recognized by MDA5 and induces type I interferon in brain macrophages/microglia. J. Virol. 82, 9829–9838 (2008).
Totura, A. L. et al. Toll-like receptor 3 signaling via TRIF contributes to a protective innate immune response to severe acute respiratory syndrome coronavirus infection. mBio 6, e00638–00615 (2015).
Mazaleuskaya, L., Veltrop, R., Ikpeze, N., Martin-Garcia, J. & Navas-Martin, S. Protective role of Toll-like receptor 3-induced type I interferon in murine coronavirus infection of macrophages. Viruses 4, 901–923 (2012).
Kawai, T. et al. IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction. Nat. Immunol. 6, 981–988 (2005).
Meylan, E. et al. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 437, 1167–1172 (2005).
Seth, R. B., Sun, L., Ea, C. K. & Chen, Z. J. Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF 3. Cell 122, 669–682 (2005).
Xu, L. G. et al. VISA is an adapter protein required for virus-triggered IFN-beta signaling. Mol. Cell 19, 727–740 (2005).
Fitzgerald, K. A. et al. IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway. Nat. Immunol. 4, 491–496 (2003).
Rehwinkel, J. & Gack, M. U. RIG-I-like receptors: their regulation and roles in RNA sensing. Nat. Rev. Immunol. 13, 1–15 (2020).
Yan, N. & Chen, Z. J. Intrinsic antiviral immunity. Nat. Immunol. 13, 214–222 (2012).
Fitzgerald, K. A. & Kagan, J. C. Toll-like receptors and the control of immunity. Cell 180, 1044–1066 (2020).
Sun, L., Liu, S. & Chen, Z. J. SnapShot: pathways of antiviral innate immunity. Cell 140, 436–436 (2010).
MacMicking, J. D. Interferon-inducible effector mechanisms in cell-autonomous immunity. Nat. Rev. Immunol. 12, 367–382 (2012).
Knoops, K. et al. SARS-coronavirus replication is supported by a reticulovesicular network of modified endoplasmic reticulum. PLoS Biol. 6, e226 (2008).
Snijder, E. J. et al. Ultrastructure and origin of membrane vesicles associated with the severe acute respiratory syndrome coronavirus replication complex. J. Virol. 80, 5927–5940 (2006).
Siu, K. L. et al. Middle east respiratory syndrome coronavirus 4a protein is a double-stranded RNA-binding protein that suppresses PACT-induced activation of RIG-I and MDA5 in the innate antiviral response. J. Virol. 88, 4866–4876 (2014).
Frieman, M., Ratia, K., Johnston, R. E., Mesecar, A. D. & Baric, R. S. Severe acute respiratory syndrome coronavirus papain-like protease ubiquitin-like domain and catalytic domain regulate antagonism of IRF3 and NF-kappaB signaling. J. Virol. 83, 6689–6705 (2009).
Frieman, M. et al. Severe acute respiratory syndrome coronavirus ORF6 antagonizes STAT1 function by sequestering nuclear import factors on the rough endoplasmic reticulum/Golgi membrane. J. Virol. 81, 9812–9824 (2007).
Kumar, P. et al. The nonstructural protein 8 (nsp8) of the SARS coronavirus interacts with its ORF6 accessory protein. Virology 366, 293–303 (2007).
Kopecky-Bromberg, S. A., Martinez-Sobrido, L., Frieman, M., Baric, R. A. & Palese, P. Severe acute respiratory syndrome coronavirus open reading frame (ORF) 3b, ORF 6, and nucleocapsid proteins function as interferon antagonists. J. Virol. 81, 548–557 (2007).
D’Elia, R. V., Harrison, K., Oyston, P. C., Lukaszewski, R. A. & Clark, G. C. Targeting the “cytokine storm” for therapeutic benefit. Clin. Vaccine Immunol. 20, 319–327 (2013).
Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497–506 (2020).
Wang, D. et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 323, 1061–1069 (2020).
Zhou, Z. et al. Heightened innate immune responses in the respiratory tract of COVID-19 patients. Cell Host Microbe 27, 883–890 (2020).
Zou, L. et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N. Engl. J. Med. 382, 1177–1179 (2020).
de Wit, E., van Doremalen, N., Falzarano, D. & Munster, V. J. SARS and MERS: recent insights into emerging coronaviruses. Nat. Rev. Microbiol. 14, 523–534 (2016).
Gordon, D. E. et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature https://doi.org/10.1038/s41586-020-2286-9 (2020).
Fehr, A. R. & Perlman, S. Coronaviruses: an overview of their replication and pathogenesis. Methods Mol. Biol. 1282, 1–23 (2013).
Daniel, B. M. et al. SARS-CoV-2 launches a unique transcriptional signature from in vitro, ex vivo, and in vivo systems. Preprint at https://doi.org/10.1101/2020.03.24.004655.
Reghunathan, R. et al. Expression profile of immune response genes in patients with severe acute respiratory syndrome. BMC Immunol. 6, 2 (2005).
Emily, K. et al. Potent antiviral activities of type I interferons to SARS-CoV-2 infection. Preprint at https://doi.org/10.1101/2020.04.02.022764.
Kumari, G. et al. SARS-CoV-2 is sensitive to type I interferon pretreatment. Preprint at https://doi.org/10.1101/2020.03.07.982264.
Lei, X. et al. The 3C protein of enterovirus 71 inhibits retinoid acid-inducible gene I-mediated interferon regulatory factor 3 activation and type I interferon responses. J. Virol. 84, 8051–8061 (2010).
Xiao, X. et al. Enterovirus 3A facilitates viral replication by promoting phosphatidylinositol 4-kinase IIIbeta-ACBD3 interaction. J. Virol. https://doi.org/10.1128/JVI.00791-17 (2017).
This work was supported by grants from the National Major Sciences & Technology Project for Control and Prevention of Major Infectious Diseases in China (2018ZX10301401 to X.L. and Z. Zhou, 2018ZX10733403 to Z.X.), the National Natural Science Foundation of China (81930063, 81971948, 31670169 to J.W., X.L., and Z. Zhou), National Key R&D Program of China (2020YFA0707600 to X.L.), Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences (2016-I2M-1-014, 2016-I2M-1-005 to J.W. and X.L.), and the Beijing Advanced Innovation Center for Genomics (ICG).
The authors declare no competing interests.
Peer review information Nature Communications thanks Steve Goodbourn and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Peer reviewer reports are available.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Lei, X., Dong, X., Ma, R. et al. Activation and evasion of type I interferon responses by SARS-CoV-2. Nat Commun 11, 3810 (2020). https://doi.org/10.1038/s41467-020-17665-9
This article is cited by
Structural and non-structural proteins in SARS-CoV-2: potential aspects to COVID-19 treatment or prevention of progression of related diseases
Cell Communication and Signaling (2023)
Cell & Bioscience (2023)
Nanostructures for prevention, diagnosis, and treatment of viral respiratory infections: from influenza virus to SARS-CoV-2 variants
Journal of Nanobiotechnology (2023)
Cellular & Molecular Immunology (2023)
Nature Communications (2023)